title: Effects of Ginkgo biloba extract on inflammatory mediators (SOD, MDA, TNF-alpha, NF-kappaBp65, IL-6) in TNBS-induced colitis in rats.
abstract: Inflammatory mediators play a critical role in ulcerative colitis immune and inflammatory processes. The aim of the study was to investigate the effects of Ginkgo biloba extract on inflammatory mediators (SOD, MDA, TNF-alpha, NF-kappaBp65, IL-6) in TNBS-induced colitis in rats. Colitis in rats was induced by colonic administration with 2,4,6-trinitrobenzene sulfonic acid (TNBS, 150 mg/kg). EGB in doses of (50, 100, 200 mg/kg) was administered for 4 weeks to protect colitis. The results showed that EGB could significantly ameliorate macroscopic and histological damage, evidently elevate the activities of SOD and reduce the contents of MDA, inhibit the protein and mRNA expressions of TNF-alpha, NF-kappaBp65, and IL-6 in the colon tissues of experimental colitis in a dose-dependent manner compared with the model group. We concluded that the probable mechanisms of EGB ameliorated inflammatory injury in TNBS-induced colitis in rats by its modulation of inflammatory mediators and antioxidation.
authors: Department of Gastroenterology, Renmin Hospital, Wuhan University, Hubei Province, China.
authors: Yan-Hong
authors: YH
authors: Zhou
authors: Jie-Ping
authors: JP
authors: Yu
authors: Yi-Fei
authors: YF
authors: Liu
authors: Xiao-Jun
authors: XJ
authors: Teng
authors: Mei
authors: M
authors: Ming
authors: Peng
authors: P
authors: Lv
authors: Ping
authors: P
authors: An
authors: Shi-Quan
authors: SQ
authors: Liu
authors: Hong-Gang
authors: HG
authors: Yu
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology; D001483:Base Sequence; D003092:Colitis / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D020441:Ginkgo biloba; D018836:Inflammation Mediators / Q000378:metabolism*; D015850:Interleukin-6 / Q000235:genetics / Q000378:metabolism; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D019804:Mesalamine / Q000008:administration & dosage / Q000494:pharmacology; D008517:Phytotherapy; D010936:Plant Extracts / Q000008:administration & dosage / Q000494:pharmacology; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013482:Superoxide Dismutase / Q000378:metabolism; D051996:Transcription Factor RelA / Q000235:genetics / Q000378:metabolism; D014302:Trinitrobenzenesulfonic Acid / Q000633:toxicity; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000378:metabolism
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000975:Antioxidants; D018836:Inflammation Mediators; D015850:Interleukin-6; D010936:Plant Extracts; D012333:RNA, Messenger; D051996:Transcription Factor RelA; D014409:Tumor Necrosis Factor-alpha; D019804:Mesalamine; D008315:Malondialdehyde; D014302:Trinitrobenzenesulfonic Acid; D013482:Superoxide Dismutase